Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PNP | P00491 | 5/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097438 | 0.78 | XDH (0.55) | XDHMEN1KMT2APNPTK1 | |
| SCHEMBL1286945 | 0.78 | XDH (1.00) | XDHMEN1KMT2APNPTK1 | |
| Hydrochloric Acid SCHEMBL21799342 | 0.77 | XDH (0.97) | XDHMEN1KMT2APNPTK1 | |
| SCHEMBL9798103 | 0.76 | PNP (0.66) | PNPTK1USP2TSHREDNRA | |
| Hydrochloric Acid SCHEMBL17186373 | 0.75 | PNP (0.65) | PNPTK1USP2TSHREDNRA | |
| SCHEMBL11610794 | 0.75 | XDH (0.69) | XDHMEN1KMT2APNPTK1 | |
| SCHEMBL27881952 | 0.74 | XDH (0.76) | XDHMEN1KMT2APNPTK1 | |
| SCHEMBL637360 | 0.74 | XDH (0.67) | XDHMEN1KMT2APNPTK1 | |
| Hydrochloric Acid SCHEMBL17186289 | 0.73 | PNP (0.56) | PNPTK1USP2TSHREDNRA | |
| SCHEMBL3310025 | 0.73 | XDH (0.76) | XDHMEN1KMT2APNPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006096995-A1 | SULFUR OLIGONUCLEOTIDES HAVING ANTIVIRAL ACTIVITIES | REPLICOR INC. (CA) | 2006-09-21 | — | — | WO | claimed |
| US-12031131-B2 | RNA-editing oligonucleotides and uses thereof | KORRO BIO, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4363574-A1 | METHODS AND COMPOSITIONS FOR ADAR-MEDIATED EDITING | Korro Bio, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4363575-A1 | METHODS AND COMPOSITIONS FOR ADAR-MEDIATED EDITING | Korro Bio, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4341405-A1 | METHODS AND COMPOSITIONS FOR ADAR-MEDIATED EDITING | Korro Bio, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2022256283-A9 | METHODS FOR RESTORING PROTEIN FUNCTION USING ADAR | KORRO BIO, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230340464-A1 | RNA-Editing Oligonucleotides and Uses Thereof | KORRO BIO, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230332143-A1 | RNA-Editing Oligonucleotides and Uses Thereof | KORRO BIO, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230295614-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF ARGININOSUCCINATE LYASE (ASL) | KORRO BIO, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295664-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | KORRO BIO, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20090197337-A1 | Methods for the production of multimeric proteins and related compositions | SEMBIOSYS GENETICS INC. (CA) | 2009-08-06 | — | — | US | disclosed |
| WO-2006096995-A1 | SULFUR OLIGONUCLEOTIDES HAVING ANTIVIRAL ACTIVITIES | REPLICOR INC. (CA) | 2006-09-21 | — | — | WO | disclosed |
| US-7098383-B2 | Methods for the production of multimeric immunoglobulins, and related compositions | SEMBIOSYS GENETICS INC. (CA) | 2006-08-29 | — | — | US | disclosed |
| US-20060179514-A1 | Methods for the production of multimeric protein complexes, and related compositions | SEMBIOSYS GENETICS, INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1346056-A1 | METHODS FOR THE PRODUCTION OF MULTIMERIC PROTEINS, AND RELATED COMPOSITIONS | SemBioSys Genetics Inc. (CA) | 2003-09-24 | — | — | EP | disclosed |
| US-20030167524-A1 | Methods for the production of multimeric protein complexes, and related compositions | SEMBIOSYS GENETICS, INC. (CA) | 2003-09-04 | — | — | US | disclosed |
| US-20030093832-A1 | Methods for the production of multimeric immunoglobulins, and related compositions | SEMBIOSYS GENETICS INC. (CA) | 2003-05-15 | — | — | US | disclosed |
| WO-2002050289-A9 | METHODS FOR THE PRODUCTION OF MULTIMERIC PROTEINS, AND RELATED COMPOSITIONS | SEMBIOSYS GENETICS INC (CA) | 2003-04-17 | — | — | WO | disclosed |
| WO-2002050289-A1 | METHODS FOR THE PRODUCTION OF MULTIMERIC PROTEINS, AND RELATED COMPOSITIONS | SEMBIOSYS GENETICS, INC. (CA) | 2002-06-27 | — | — | WO | disclosed |
| US-20020037303-A1 | Thioredoxin and thioredoxin reductase containing oil body based products | SEMBIOSYS GENETICS INC. (CA) | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230332143-A1 | RNA-Editing Oligonucleotides and Uses Thereof | ADAR, NSUN3, NSUN2 | XDH 815/4885MEN1 3538/4885KMT2A 1327/4885 |
| US-20230295614-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF ARGININOSUCCINATE LYASE (ASL) | ADAR, ADA, ASS1 | XDH 428/4885MEN1 4641/4885KMT2A 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.